Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
(MedPage Today) -- ORLANDO -- Adding a personalized cancer vaccine to anti-PD-1 immunotherapy for resectable melanoma led to a 44% improvement in recurrence-free survival (RFS) versus immunotherapy alone, according to a study reported here....
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Dermatology | Immunotherapy | Melanoma | Skin | Skin Cancer | Study | Vaccines